HPV Associated Disorders Market To Reach $28.5 Billion By 2033

HPV Associated Disorders Market Growth & Trends

The global HPV associated disorders market size is expected to reach USD 28.5 billion by 2033, registering a CAGR of 4.9% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market is driven by an increase in disease prevalence and emergence of targeted therapies.

Most cancers associated with HPV have high mortality rates. For instance, cervical cancer has a mortality rate of over 50%. Cervical Intraepithelial Neoplasia (CIN) and Anal Intraepithelial Neoplasia (AIN) could advance into cervical and anal cancer, respectively, in the absence of timely treatment. However, these cancers generally have a slow progression rate, providing possibilities for prevention and treatment.

The prevalence of HPV infection-especially in young women-has increased in the recent decades and continues to increase. Globally, cervical cancer stands as the fourth most prevalent cancer in women. Since HPV is a major causative factor for this, the increasing disease prevalence is a key driving force for market growth.

It is estimated that more than 430 million women in India-15 years or above-are considered at risk for developing HPV associated disorders. The annual incidence of these diseases among Indian women is over 122,900 and disease mortality is around 68,000. In the ancillary market of cervical cancer, India records the highest age-standardized disease incidence in South Asia at 22, followed by Bangladesh at 19.2, Sri Lanka at 13, and Iran at 2.8.

Proactive government initiatives and rise in consumer awareness are likely to drive growth. The CDC initiated National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991. The program was created to promote & and facilitate low-cost or free screening for women. Along similar lines, the Indian government recently started an operational framework for mandatory screening for cervical, breast, and oral cancer in people aged 30 years or more. The initiative marked the first nationwide oncological screening program.

 Request a free sample copy or view report summary: HPV Associated Disorders Market Report

HPV Associated Disorders Market Report Highlights

• The cervical cancer segment dominated the market with the largest revenue share of 34.7% in 2025, due to the strong clinical association between persistent high-risk HPV infections and cervical malignancies.

• The vaccines segment dominated the market with the largest revenue share of 63.8% in 2025, due to increasing global emphasis on preventive healthcare and long-term reduction of HPV-related cancer burden.

• The retail pharmacies segment is projected to grow at a significant CAGR of 5.1% over the forecast period, driven by increasing outpatient care and follow-up treatment after hospital-based diagnosis.

• North America held the largest HPV associated disorders market share of 37.4% in 2025 driven by the region’s well-established cervical cancer screening infrastructure, high uptake of HPV vaccination programs, and rapid adoption of advanced molecular diagnostic technologies.

HPV Associated Disorders Market Segmentation

Grand View Research has segmented the global HPV associated disorders market based on type, treatment, distribution channel, and region:

HPV Associated Disorders Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Cervical Intraepithelial Neoplasia (CIN)

• Cervical Cancer

• Anal Intraepithelial Neoplasia (AIN)

• Anal Cancer

• Genital Warts

• Others

HPV Associated Disorders Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

• Vaccines

• Anti-viral Drugs

• Others

HPV Associated Disorders Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospital Pharmacies

• Retail Pharmacies

• Others

HPV Associated Disorders Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the HPV Associated Disorders Market

• Merck & Co., Inc.

• GlaxoSmithKline plc

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

• AstraZeneca

• Biocon

• Lilly

• AbbVie Inc.